Clinical Trial

Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare

Study acronym: AppGERD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising potential in supporting chronic disease management and improving patient outcomes. The GERDCare mobile application was developed with direct input from gastrointestinal experts. It is designed to enhance treatment adherence and patient engagement by offering features such as educational resources, symptom tracking, medication reminders, and direct communication between patients and physicians. The investigators are conducting a single-center, open-label, randomized controlled trial to evaluate the effectiveness of using GERDCare in improving patient adherence. Patients are followed up after four weeks of GERD treatment.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-30 -> 2026-07-31 2026-06-18
minor Completion pushed: 2026-05-31 -> 2026-08-31 2026-06-18
Trial Details
NCT Number NCT07125521
Lead Sponsor Institute of Gastroenterology and Hepatology, Vietnam
Conditions GERD (Gastroesophageal Reflux Disease)
Enrollment 380 participants
Start Date 2025-08-18
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-17